Leading research institutions and hospitals across London, including King’s, will unite to transform the care of lung cancer with plans to invite patients over a population of six million into a pioneering new programme of clinical trials.
The London Lung Cancer Alliance, launched today, is backed by the Mayor of London, Boris Johnson, and by England’s Chief Medical Officer, Professor Dame Sally Davies. The Alliance aims to deliver dramatic benefits for patients in London, nationally and worldwide – through collaboration, coordination and an ambition to give every patient access to a trial suitable for them.
Member organisations plan a programme of research that will ultimately make trials of cutting-edge personalised therapies available to up to 3,000 patients a year newly diagnosed with lung cancer across the capital.
Lung cancer is the second most commonly diagnosed cancer in the UK after breast cancer, with 42,000 new cases in 2010. Survival rates in the UK are distressingly low and worse than across much of Europe – less than 10% of patients are still alive five years after diagnosis.
In addition to King’s College London (as part of King’ Health Partners Academic Health Sciences Centre), the Alliance of research institutions and hospitals includes Imperial College London, Imperial College Healthcare NHS Trust, Royal Brompton & Harefield NHS Foundation Trust, The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust, St George’s Healthcare NHS Trust and Barts Cancer Institute at Queen Mary, University of London.
Patients with lung cancer across London will be included in the unique research programme, which will cover the entire lung cancer pathway from the identification and screening of those at risk through to end-stage disease. The London Lung Cancer Alliance will also link up with five other cities across the UK.
Researchers will genetically profile tumours and test a panel of targeted therapies – many previously untried in lung cancer - in those with particular molecular defects. They will also develop ‘liquid biopsy’ blood tests for patients who are too ill to biopsy, or to monitor whether drugs are working and assess for signs of resistance.
Under the plans, all patients within a six-million catchment area in London, along with those in Newcastle, Southampton, Liverpool, Cardiff and Edinburgh, will eventually be offered gene testing of their cancers at diagnosis. As many patients as possible will then be offered one of a panel of targeted therapies matched to their cancer’s particular molecular defects.
Dr James Spicer, Reader in Experimental Oncology at King's College London, said: ‘The explosion in our understanding of lung cancer biology is at last leading to a growing list of experimental treatment options for lung cancer. ‘Now we need a new level of organisation and collaboration to introduce these drugs to the clinic as soon as possible, and provide these previously disadvantaged patients with new hope. King’s Health Partners is delighted to play a part in making this happen.’
Boris Johnson, Mayor of London, said: ‘London is a global leader in medical research and the life sciences, with world-class hospitals and other institutions investigating treatments for lung cancer. By working together they are multiplying the knowledge and expertise required to develop trials of therapies targeting a disease that affects far too many people living in the capital.’
Professor Dame Sally Davies, Chief Medical Officer for England, said: ‘The launch of this Alliance heralds a brighter future for lung cancer patients across London and more widely and is just the kind of collaborative initiative that we're keen to see National Institute for Health Research infrastructure support. It is only by academia, the NHS and industry working together that we can make real progress against diseases such as lung cancer, where low expectations and poor survival rates have become entrenched.’
All the organisations in the London Lung Cancer Alliance have pledged to allocate funding for the infrastructure required by the initiative, with further funding to be sought from a series of grant-giving bodies, including the Government.
The Alliance plans to work with pharmaceutical companies to make existing targeted cancer therapies available to be tested in lung cancer for the first time.
Some of these drugs are targeted at molecular defects that may only be present in a small proportion of lung cancers, which is why it is so important to include such large numbers of patients in the trial programme. By providing access to a wide range of treatments, it should be possible to match many patients in the trial programme to a potentially effective drug.
The Alliance also plans to focus on screening, early detection and prevention of lung cancer across high-risk groups, including patients with chronic obstructive pulmonary disease (COPD).
Notes to editors
For further media information please contact Emma Reynolds, PR Manager (Health) at King’s College London, on 0207 848 4334 or email emma.reynolds@kcl.ac.uk.
For further information about King's please visit our 'King's in Brief' page.
